Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Pirarubicin (THP) is a new generation cell cycle nonspecific anthracycline anticancer drug. Pirarubicin and pirarubicin-based combination therapies have been demonstrated to be effective against HCC in TACE. However, the drug resistance limits its therapeutic efficacy. Receptor-interacting protein kinase 1 (RIPK1) displays a critical role in cell death. | RIPK1 inhibition enhances pirarubicin cytotoxic efficacy through AKT-P21-dependent pathway in hepatocellular carcinoma
